A California aesthetics practice sits on an underused asset: a base of patients who already trust it with medical treatment. Medical weight management and hormone therapy are the natural extension — but California is the state where adding them badly creates the most exposure.
Here is how to add revenue without breaking a structure that California now polices with an enforcement statute.
The commercial case
Injectables are episodic. A patient returns every three or four months and the relationship resets each time.
Weight management and hormone therapy are ongoing programs — monthly contact, follow-up labs, dose adjustments. The same patient interacts with the practice several times more often per year, for clinical reasons rather than promotional ones.
You are not buying new patients. You are increasing the annual value of the ones you already earned.
What California requires you not to break
California enforces the corporate practice of medicine strictly, and since January 1, 2026, SB 351 restricts management-side control over clinical decisions with Attorney General enforcement behind it.
Practically, adding a prescribing service line raises the stakes on the boundary you already have:
- The PC decides what is prescribed. Not the MSO, not the owner, not a protocol drafted by the marketing side.
- No volume targets on clinical output. A weight-management program with a monthly approval quota is exactly what the statute addresses.
- Real evaluations that can end in no. Some patients are not candidates. A program that never declines anyone is not evaluating.
- Records inside the PC. More services means more records — all on the clinical side.
- Fees stay fair market value. Do not let a new revenue line pull you into percentage-of-clinical-revenue compensation.
Where the margin comes from
| Lever | Effect |
|---|---|
| Visit frequency | Monthly contact instead of quarterly — the largest single driver |
| Retention | Monitored programs hold patients; refill mills churn |
| In-house labs | Removes the send-out step where programs lose people |
| Sourcing leverage | Menu discipline plus group volume, not per-unit negotiation |
| Cross-sell | Your weight-management patient is already an aesthetics patient |
| Provider utilisation | Structured follow-up reserves clinician time for real decisions |
Product markup is the smallest lever and the one competitors can match fastest. Frequency and retention are where the durable economics sit.
What you actually have to stand up
- Protocols specific to weight management and hormone therapy, authored inside the PC. Your injectables protocol does not cover semaglutide.
- Providers licensed in California with authority to prescribe, working within current scope rules.
- An evaluation workflow — a real good faith exam before any prescription.
- Lab baselines and follow-up, ideally drawn on site.
- Documented pharmacy sourcing, 503A or 503B depending on whether preparations are patient-specific or office stock.
- Monitoring and follow-up scheduled by the practice, not left to the patient.
- Marketing that describes a clinical program and does not promise outcomes.
The mistakes that cost the most in California
- Launching before the PC is genuinely in charge. A new prescribing line on a paper-thin structure compounds the original problem.
- Approval quotas. Now squarely in the statute’s sights.
- Outcome marketing. Guaranteed results is an advertising problem and a clinical one.
- Refills without monitoring. Churns patients and creates liability at the same time.
- Menu sprawl. Too many compounds and concentrations destroys sourcing leverage.
- Treating labs as optional for hormones. They are not.
What MDside provides in California
The professional corporation and the physician owner of record, licensed California providers performing evaluations and prescribing, protocols authored and held inside the PC, 503A and 503B pharmacy relationships, lab integration including in-house draws, and the review workflow on software we build and own.
You add the service line and keep your brand and your commercial economics. The clinical entity carries the clinical responsibility — which, in California, is the entire point.
See what is included, or read about what SB 351 changed.
Frequently asked questions
Can my California med spa add GLP-1 weight management?
Yes, provided the prescribing sits inside a properly operating professional corporation with licensed providers, real evaluations, and protocols owned on the clinical side.
Does SB 351 stop me from adding services?
No. It restricts management-side control over clinical decisions. Adding a service is fine; letting the management entity decide who gets prescribed is not.
Do I need labs?
Effectively yes for hormone therapy, and strongly advisable for weight management. Drawing on site removes the biggest drop-off point.
How do I bring medication costs down?
Consolidate the menu, forecast volume, and source through a group rather than as a single location.
Who owns the patients?
Clinically, the professional corporation holds the records and the provider relationship. Commercially, the brand and the customer relationship remain yours.
General information, not legal, clinical, or financial advice. California corporate practice and scope rules are strict and changing. Confirm with healthcare counsel licensed in California.